BiotechTube

INCMGA00012 + Palbociclib

Phase 2Active
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Well-differentiated/Dedifferentiated Liposarcoma

Conditions

Well-differentiated/Dedifferentiated Liposarcoma

Trial Timeline

Jun 17, 2020 → Jun 1, 2026

NCT ID
NCT04438824

About INCMGA00012 + Palbociclib

INCMGA00012 + Palbociclib is a phase 2 stage product being developed by Incyte for Well-differentiated/Dedifferentiated Liposarcoma. The current trial status is active. This product is registered under clinical trial identifier NCT04438824. Target conditions include Well-differentiated/Dedifferentiated Liposarcoma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT04438824Phase 2Active

Other Products from Incyte

ruxolitinib creamApproved
82
Itacitinib + Placebo + Prednisone + MethylprednisolonePhase 3
74
Povorcitinib + PlaceboPhase 3
74
Ruxolitinib Cream + Vehicle CreamPhase 3
74
Tacrolimus (Tac) + Methotrexate (MTX) + Ruxolitinib (Rux) + Cyclophosphamide + Mycophenolate mofetil (MMF)Phase 3
74